Targeted therapy in BRAF -mutated lung adenocarcinoma

Targets need to be validated by disease site, as highlighted by the fact that BRAF inhibitors have minimum activity in BRAF-mutated colon cancer.4 So far, use of BRAF inhibitors in patients with BRAFV600E-positive non-small-cell lung cancer (NSCLC) has been reported in a retrospective study of off-label use,5 and in a cohort of patients in a basket trial who received vemurafenib for non-melanoma cancers.4 In The Lancet Oncology, David Planchard and colleagues6 present the findings from a prospective trial that specifically enrolled patients with BRAFV600E-positive NSCLC.